Retinal vascular permeability is reduced in the eye by administration of an inhibitor of Carbonic Anhydrase-1 (CA-1) and/or Carbonic Anhydrase-2 (CA-2) and optionally an inhibitor of Vascular Endothelial Growth Factor (VEG) signalling. Compounds and methods are provided for diagnosis and treatment of associated disorders in retina and brain.